FX 002
Alternative Names: FX002Latest Information Update: 04 Mar 2022
At a glance
- Originator Unknown
- Developer Flexion Therapeutics
- Class Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 05 Feb 2010 Phase-II clinical trials in Autoimmune disorders in USA (unspecified route)